Cortical Bone Mechanics Technology to better screen for osteoporosis
Official title: Development of Cortical Bone Mechanics Technology for Enhancing the Screening of Osteoporosis
Funded at Osteodx INC. · NIH-11405859 · Data updated 2026-11-12
A new noninvasive test called CBMT uses ulnar flexural rigidity to predict fracture risk better than standard bone density tests, helping adults who may be at risk for osteoporosis.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Osteodx INC. NIH-funded |
| Lab location | 1 site (Athens, UNITED STATES) |
| Project start | September 22, 2026 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $1,769,500 |
| NIH project number | 1SB1AG102185-01 |
| Project ID | NIH-11405859 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults at risk for osteoporosis or fractures, including postmenopausal women and others undergoing screening
✕Less likely to help
Individuals without fracture risk factors or those outside the tested age ranges may not benefit from CBMT screening differences.
What this research studies
This project aims to improve osteoporosis screening beyond traditional bone density tests by using a radiation-free method called Cortical Bone Mechanics Technology (CBMT). The test measures how stiff the forearm bone is and shows strong links to overall bone strength, potentially identifying people at risk who would be missed by DXA alone. The work builds on prior NIH-funded development and moves CBMT toward automated clinical use across multiple centers. If successful, CBMT could help clinicians tailor prevention and treatment for adults at risk for fractures.
Why it matters
Potential benefit: If CBMT proves accurate in broader populations, patients could receive earlier and more precise fracture risk screening, potentially preventing fractures.
How similar studies have gone: CBMT has shown higher discrimination for fracture risk than DXA in multicenter studies, supporting continued development.
Where this research is happening
-
Osteodx INC.
Athens, United States Active
Researchers
- Principal investigator: Dick, Andrew — Osteodx INC.
- Study coordinator: Dick, Andrew
Related research
Other NIH-funded projects on the same topics.
-
Or olive-oil derived compound to prevent bone loss in women
A safe, orally taken nutraceutical may help prevent osteoporosis in adult women by supporting bone formation and reducing bone loss.
-
When to stop, switch, or pause long-term osteoporosis medicines for older adults
This project looks at whether stopping, switching, or taking breaks from long-term osteoporosis drugs changes fracture risk and side effects for older adults.
-
Gene therapy for osteoporosis linked to ALDH2 deficiency in postmenopausal East Asian women
A gene therapy approach is being developed to reduce osteoporosis risk in postmenopausal East Asian women who have ALDH2 deficiency and drink alcohol.
-
Metabolomics clues to osteoporosis risk in diverse populations
A study using small molecules in blood samples to understand osteoporosis risk, with a focus on aging, ethnicity, and sex differences.
-
Single-Cell Study of Bone Cells to Understand Osteoporosis
Researchers will study individual bone-related cells from people to uncover why aging leads to weaker bones and higher fracture risk.
-
Gut bacteria and osteoporosis risk: what gut microbes may mean for your bone health
A large study will look at how gut bacteria relate to bone density and fracture risk, with the goal of better understanding who is at risk and how to protect bones.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.